
News|Articles|September 30, 2025
Sensitive LC-MS/MS approach for the quantification of proteolysis targeting chimeras in a biological matrix
Author(s)SCIEX
Key Takeaways
- Personalized treatment strategies have advanced lung cancer brain metastases management, integrating targeted therapies and immunotherapies for improved outcomes.
- Stereotactic radiosurgery and whole-brain radiation therapy are evolving with novel systemic therapies, maintaining their importance in treatment.
PROTACs are protein degraders that harness the cell’s disposal machinery to remove specific targets. Now advancing into clinical trials, they show high potency at nanomolar levels. To support safe and effective drug development, sensitive and selective assays are essential for reliable detection and quantification.
Newsletter
Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert solutions in chromatography.
Trending on LCGC International
1
Chromatographic Extraction and LC–Triple Quadrupole Mass Spectrometric Determination of Acrylamide in Powdered Infant Formulas
2
Voices from the Analytical Front Line: Tony Edge on Chromatography in 2026
3
Velaris Announces Acquisition of Markes International
4
Voices from the Analytical Front Line: Dave Bell on Chromatography in 2026
5